Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction–associated steatohepatitis (MASH) and fibrosis

Authors: Zobair M. Younossi, Maria Stepanova, Andrei Racila, Linda Henry, Dominic Labriola, Rebecca Taub, Fatema Nader

Published: 2024-09-09

DOI: 10.1097/hep.0000000000001084

Source: Full article

---

Abstract

Background and Aims: